Compass Pathways uses psychoactive treatment for depression — CEO explains

Biotech company Compass Pathways is up more than 100 since its IPO debut. The company aims to treat depression through psychedelic mushrooms and is backed by Peter Thiel. George Goldsmith, co-founder, chairman and CEO, joins 'Power Lunch' to discuss the psychoactive treatment and the impact the coronavirus pandemic had on the company.